Vertex Pharma (VRTX): Takeaways From KOL Panel - Jefferies

September 30, 2016 8:11 AM EDT
Get Alerts VRTX Hot Sheet
Price: $76.97 +1.49%

Rating Summary:
    27 Buy, 14 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 29 | Down: 45 | New: 20
Trade VRTX Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Jefferies analyst, Brian Abrahams, reiterated his Buy rating on shares of Vertex (NASDAQ: VRTX) after hosting a CF Summit with a panel of physician/scientists and a line-up of companies across the CF space.

The analyst is more confident that 6-11yo patients should provide a near term uptick to Orkambi and that VRTX retains a healthy lead over potential CFTR competitors in improving the regimen and expanding the market.

He also found doctors remain lukewarm on Orkambi overall.

All in, the analyst still sees VRTX's CF leadership, revenue expansion opportunities, and long term operational leverage as undervalued.

No change to his price target of $104.

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

Shares of Vertex closed at $85.00 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment